First-line therapy with nivolumab and ipilimumab for advanced NSCLC drastically decreased progression in Part 1 of the randomized phase 3 CheckMate 227 trial compared to the platinum-doublet chemotherapy and significantly prolonged OS in patients with tumor PD-L1 expression ≥1% and disease-free survival in patients with a high tumor mutational load (NCT02477826, NCT02477826) (Hellmann et al., 2018; Hellmann et al., 2019). This evidence concerns the gene CD274 and non-small cell lung carcinoma.